An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05540964 |
|
Recruitment Status :
Enrolling by invitation
First Posted : September 15, 2022
Last Update Posted : December 2, 2022
|
Sponsor:
American Gene Technologies International Inc.
Information provided by (Responsible Party):
American Gene Technologies International Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Enrolling by invitation |
|---|---|
| Estimated Primary Completion Date : | July 19, 2025 |
| Estimated Study Completion Date : | July 19, 2025 |